“HER2 Breast Cancer Talk”: A Review of Data from the SABCS 2020 Virtual Symposium - Episode 1

Current Treatment Landscape for HER2+ Breast Cancer

January 25, 2021
Ruth O'Regan, MD, University of Rochester Medical Center

,
Joyce O'Shaugnessy, MD, Texas Oncology

,
Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center

,
Debu Tripathy, MD, MD Anderson Cancer Center

Breast cancer experts discuss the evolution of HER2-targeted treatments, including margetuximab, trastuzumab, tucatinib, and neratinib, along with unmet needs in patients with HER2+ breast cancer.

x